535 W 24TH STREET, NEW YORK, NY
Investor Presentation
Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Quarterly Report
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement